Publications by authors named "Philip Lowe"

Claim this Profile
T
Translation of a Human-Based Malaria-on-a-Chip Phenotypic Disease Model for In Vivo Applications.
Michael J Rupar, Hannah M Hanson, Brianna L Botlick, Narasimhan Sriram, Stephanie Rogers, Philip Lowe

Adv Sci (Weinh)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of frozen embryo transfer regimen on the association between serum progesterone and live birth: a multicentre prospective cohort study (ProFET).
Pedro Melo, Simon Wood, Georgios Petsas, Yealin Chung, Christina Easter, Philip Lowe

Hum Reprod Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum luteal phase progesterone in women undergoing frozen embryo transfer in assisted conception: a systematic review and meta-analysis.
Pedro Melo, Yealin Chung, Oonagh Pickering, Malcolm J Price, Simon Fishel, Philip Lowe

Fertil Steril· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates.
Vittal Shivva, Martin Fink, Philip J Lowe

J Pharmacokinet Pharmacodyn· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of food pellets containing 1-aminobenzotriazole for longer term in vivo inhibition of cytochrome P450 in mice.
Rowan Stringer, Valerie Cordier, Catherine Afatsawo, Philip Arabin, Sandrine Desrayaud, Philip John Lowe

Xenobiotica· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two Case Studies on How Study Designs Can Be Made More Informative Using Modeling and Simulation Approaches.
Philip J Lowe, Martin Fink, Mark N Milton

Clin Pharmacol Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
Gail M Gauvreau, Jonathan P Arm, Louis-Philippe Boulet, Richard Leigh, Donald W Cockcroft, Philip J Lowe

J Allergy Clin Immunol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion.
Wataru Honma, Aurélie Gautier, Ines Paule, Masayuki Yamaguchi, Philip J Lowe

Drug Metab Pharmacokinet· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omalizumab in asthma: an update on recent developments.
Marc Humbert, William Busse, Nicola A Hanania, Philip J Lowe, Janice Canvin

J Allergy Clin Immunol Pract· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.
Philip J Lowe, Panayiotis Georgiou, Janice Canvin

Regul Toxicol Pharmacol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicentre study of the clinical relevance of screening IVF patients for carrier status of the annexin A5 M2 haplotype.
Simon Fishel, Rashmi Patel, Alison Lytollis, Jeanette Robinson, Mary Smedley, Philip Lowe

Reprod Biomed Online· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies.
Mohamed Elmeliegy, Philip Lowe, Wojciech Krzyzanski

AAPS J· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.
Xiaoyu Yan, Philip J Lowe, Martin Fink, Alexander Berghout, Sigrid Balser

J Clin Pharmacol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
Abhijit Chakraborty, Stacey Tannenbaum, Christiane Rordorf, Philip J Lowe, David Floch

Clin Pharmacokinet· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stakeholder engagement and knowledge exchange in environmental research.
Jeremy Phillipson, Philip Lowe, Amy Proctor, Eric Ruto

J Environ Manage· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
Philip J Lowe, Didier Renard

Br J Clin Pharmacol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infectious diseases of animals and plants: an interdisciplinary approach.
Katy Wilkinson, Wyn P Grant, Laura E Green, Stephen Hunter, Michael J Jeger, Philip Lowe

Philos Trans R Soc Lond B Biol Sci· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The changing role of veterinary expertise in the food chain.
Gareth Enticott, Andrew Donaldson, Philip Lowe, Megan Power, Amy Proctor

Philos Trans R Soc Lond B Biol Sci· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.
Jing Yu, Helene Karcher, Adam L Feire, Philip J Lowe

AAPS J· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond policy networks: policy framing and the politics of expertise in the 2001 Foot and Mouth Disease crisis.
Katy Wilkinson, Philip Lowe, Andrew Donaldson

Public Adm· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction: Greening the countryside? Changing frameworks of EU agricultural policy.
Philip Lowe, Peter H Feindt, Hilkka Vihinen

Public Adm· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
Philip J Lowe, Stacey Tannenbaum, Kai Wu, Peter Lloyd, Jennifer Sims

Basic Clin Pharmacol Toxicol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A public or private profession?
Philip Lowe

Vet Rec· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.
Pawel Wiczling, Philip Lowe, Etienne Pigeolet, Frank Lüdicke, Sigrid Balser

Clin Pharmacokinet· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.
Philip J Lowe, Stacey Tannenbaum, Aurelie Gautier, Pablo Jimenez

Br J Clin Pharmacol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis